Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04515238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Study acronym: CLL2-BZAG
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Dec 2026 → Feb 2027
See other at-risk trials from German CLL Study Group

Record History

  1. Primary and study completion pushed from Dec 2026 to Feb 2027v11
  2. Primary completion date: Feb 2025 to Dec 2026v10
  3. Primary completion date: Apr 2025 to Feb 2025
    • Study completion date: Mar 2027 to Dec 2026
    v9
  4. 2 versions Re-verified since Oct 2, 2023, no change to tracked fieldsv7-v8
  5. Primary completion date: Oct 2022 to Apr 2025v6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 40 to confirmed 42
    • Study sites: 21 to 11
    • Study completion date: Sep 2025 to Mar 2027
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 2 to 21v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Sep 2020 to Oct 1, 2020
    v4
  3. 2 versions Re-verified since Aug 15, 2020, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.
Trial Details
NCT Number NCT04515238
Lead Sponsor German CLL Study Group
Conditions
(from sponsor)		 Chronic Lymphoid Leukemia
Related terms Leukemia, B-Cell
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov